SCHEMBL21730552

SCHEMBL21730552

CC/C=C/C(=O)NCC1CCN(CC)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 4/20 0.49
EPHX2 P34913 3/20 0.49
SMN1; SMN2 Q16637 1/20 0.40
HDAC3 O15379 2/20 0.40
HDAC4 P56524 2/20 0.40
HDAC1 Q13547 2/20 0.40
HDAC7 Q8WUI4 2/20 0.40
HDAC2 Q92769 2/20 0.40
HDAC10 Q969S8 2/20 0.40
HDAC11 Q96DB2 2/20 0.40
HDAC8 Q9BY41 2/20 0.40
HDAC6 Q9UBN7 2/20 0.40
HDAC9 Q9UKV0 2/20 0.40
HDAC5 Q9UQL6 2/20 0.40
MAOA P21397 1/20 0.39
MAOB P27338 1/20 0.39
KCNH2 Q12809 3/20 0.38
CACNA1I Q9P0X4 3/20 0.38
SLC2A1 P11166 1/20 0.35
ALOX15 P16050 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21730551 0.86 EPHX1 (0.50) EPHX1EPHX2SMN1; SMN2HDAC3HDAC4
SCHEMBL19975260 0.85 TDP1 (0.45) EPHX1SMN1; SMN2MAOAMAOBALOX15
SCHEMBL19975262 0.81 KMT2A (0.49) EPHX1EPHX2ALOX15TSHRKMT2A
SCHEMBL16306645 0.77 EPHX1 (0.56) EPHX1EPHX2SMN1; SMN2KCNH2CACNA1I
SCHEMBL2053924 0.77 EPHX1 (0.56) EPHX1EPHX2SMN1; SMN2HDAC3HDAC4
SCHEMBL13492972 0.76 EPHX1 (0.55) EPHX1EPHX2SMN1; SMN2HDAC3HDAC4
SCHEMBL20807875 0.74 EPHX1 (0.61) EPHX1EPHX2SMN1; SMN2KCNH2CACNA1I
SCHEMBL22169803 0.74 EPHX1 (0.54) EPHX1EPHX2SMN1; SMN2KCNH2CACNA1I
SCHEMBL18134845 0.73 EPHX1 (0.52) EPHX1EPHX2SMN1; SMN2HDAC3HDAC4
SCHEMBL22169792 0.73 EPHX1 (0.52) EPHX1EPHX2SMN1; SMN2KCNH2CACNA1I

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11731986-B2 Inhibitors of low molecular weight protein tyrosine phosphatase (LMPTP) and uses thereof Sanford Burnham Prebys Medical Discovery Institute (US) 2023-08-22 US disclosed
US-20230029557-A1 INHIBITORS OF LOW MOLECULAR WEIGHT PROTEIN TYROSINE PHOSPHATASE (LMPTP) AND USES THEREOF Sanford Burnham Prebys Medical Discovery Institute 2023-02-02 US disclosed
US-11066420-B2 Inhibitors of low molecular weight protein tyrosine phosphatase (LMPTP) and uses thereof Sanford Burnham Prebys Medical Discovery Institute (US) 2021-07-20 US disclosed
US-20200055875-A1 INHIBITORS OF LOW MOLECULAR WEIGHT PROTEIN TYROSINE PHOSPHATASE (LMPTP) AND USES THEREOF NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2020-02-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230029557-A1 INHIBITORS OF LOW MOLECULAR WEIGHT PROTEIN TYROSINE PHOSPHATASE (LMPTP) AND USES THEREOF ACP1, PTPRCAP, PTPRO EPHX1 3316/4885EPHX2 4474/4885SMN1; SMN2 4733/4885
US-11731986-B2 Inhibitors of low molecular weight protein tyrosine phosphatase (LMPTP) and uses thereof ACP1, PTPRCAP, PTPRO EPHX1 3316/4885EPHX2 4474/4885SMN1; SMN2 4733/4885
US-20200055875-A1 INHIBITORS OF LOW MOLECULAR WEIGHT PROTEIN TYROSINE PHOSPHATASE (LMPTP) AND USES THEREOF ACP1, PTPRCAP, PTPRO EPHX1 3316/4885EPHX2 4474/4885SMN1; SMN2 4733/4885
US-11066420-B2 Inhibitors of low molecular weight protein tyrosine phosphatase (LMPTP) and uses thereof ACP1, PTPRCAP, PTPRO EPHX1 3316/4885EPHX2 4474/4885SMN1; SMN2 4733/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.